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Abstract
Purpose—Invasive ductal carcinoma (IDC) is diagnosed with or without a ductal carcinoma in 
situ (DCIS) component. Previous analyses have found significant differences in tumor 
characteristics between pure IDC lacking DCIS and mixed IDC with DCIS. We will test our 
hypothesis that pure IDC represents a form of breast cancer with etiology and risk factors distinct 
from mixed IDC/DCIS.
Methods—We compared reproductive risk factors for breast cancer risk, as well as family and 
smoking history between 831 women with mixed IDC/DCIS (n=650) or pure IDC (n=181), and 
1,620 controls, in the context of the Women's Circle of Health Study (WCHS), a case-control 
study of breast cancer in African-American and European-American women. Data on reproductive 
and lifestyle factors were collected during interviews, and tumor characteristics were abstracted 
from pathology reports. Case-control and case-case analyses were conducted using unconditional 
logistic regression.
Results—Most risk factors were similarly associated with pure IDC and mixed IDC/DCIS. 
However, among postmenopausal women, risk for pure IDC was lower in women with body mass 
index (BMI) 25 to <30 kg/m2 (Odds Ratio (OR)=0.66; 95% confidence interval (CI), 0.35-1.23) 
and BMI≥30 kg/m2 (OR=0.33; 95% CI, 0.18-0.67) compared to women with BMI<25 kg/m2, with 
no associations with mixed IDC/DCIS. In case-case analyses, women who breastfed up to 12 
months (OR=0.55; 95% CI, 0.32-0.94) or longer (OR=0.47; 95% CI, 0.26-0.87) showed decreased 
odds of pure IDC than mixed IDC/DCIS compared to those who did not breastfeed.
Conclusions—Associations with some breast cancer risk factors differed between mixed IDC/
DCIS and pure IDC, potentially suggesting differential developmental pathways. These findings, 
if confirmed in a larger study, will provide a better understanding of the development patterns of 
breast cancer and the influence of modifiable risk factors, which in turn could lead to better 
preventive measures for pure IDC, which have worse disease prognosis compared to mixed IDC/
DCIS.
Keywords
Breast cancer; Ductal carcinoma in situ component; Risk factors; Cancer etiology; Cancer 
pathology
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Breast cancer develops as a result of multiple genetic changes in epithelial cells lining the 
mammary duct concurrent with changes in the surrounding stroma [1-3]. Invasive carcinoma 
is thought to develop through a linear succession of morphological changes from normal 
cells to atypical hyperplasia, to carcinoma in situ, and then becoming invasive as the lesion 
breaks through the basement membrane of the duct. However, breast cancer is a 
heterogeneous disease, and it is unlikely that all invasive breast tumors progress through the 
same course of development. Evidence suggests that for a proportion of carcinomas, 
progression is accelerated, resulting in the development of pure invasive ductal carcinoma 
(IDC) that either arise de novo or without an extended period of containment, often 
occurring between regular mammography screenings as interval tumors [4, 5]. Previous 
evidence suggests that IDC with accompanying DCIS may represent a distinct clinical and 
biological entity from pure IDC [6]. Pure invasive carcinoma, in comparison to mixed 
invasive carcinoma with DCIS, are larger, higher grade, have higher Ki-67 expression, 
fewer calcifications, and are more frequently negative for expression of estrogen receptor 
(ER) and human epidermal growth receptor 2 (HER2) [6-12]. Castro and colleagues found a 
substantial number of differentially expressed genes in pure DCIS compared with those 
expressed in mixed IDC/DCIS [13] and some studies suggest that the presence of a DCIS 
component is associated with cell-mediated immune changes in the microenvironment and 
neoplastic epithelial cells surrounding the DCIS leading to differences in tumor progression 
and improved prognosis [6, 9-10, 14-16]. Pure IDC has also been associated with younger 
age [7, 9, 10] and worse survival outcomes [7, 9, 17-18], although inconsistencies among 
studies for these factors exist [7-10, 17-18]. In addition, significant differences in the levels 
of matrix metalloproteinase expression have been observed between the tumor and stromal 
cells of mixed IDC/DCIS and pure IDC in histological studies [19, 20]. In sum, these 
differences in tumor characteristics and protein expression suggest potential differences in 
etiologic risk factors for mixed IDC/DCIS and pure IDC. Common risk factors for breast 
cancer, such as older age at menarche, nulliparity, older age at first birth, breast cancer in a 
first degree relative, and higher postmenopausal body mass index (BMI) are consistently 
associated with increased overall risk of invasive breast cancer [21-25], however, the impact 
of these factors on the presence or absence of concomitant DCIS remain largely unknown.
In this study, we evaluated potential risk factors associated with mixed IDC/DCIS and pure 
IDC in women in the Women's Circle of Health Study (WCHS), which was specifically 
designed to evaluate risk factors for early and aggressive breast cancer in African American 
(AA) compared to European American (EA) women [26-29]. We additionally examined 
screening practices and ER status to control for the possibility of an association between 
lack of screening and pure IDC, and the possibility that absence of a DCIS component is 
simply characteristic of ER negative tumors. Differences in risk factor profiles would 
provide evidence that mixed IDC/DCIS and pure IDC are biologically distinct diseases with 
potentially different etiologic pathways. A better understanding of the developmental 
patterns of breast cancer may offer more effective preventive measures and treatment 
options.
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Study population and data
These analyses are based in the WCHS, a multi-center case-control study of breast cancer in 
AA and EA women, conducted in metropolitan New York City (NYC) from 2002 through 
2008, and seven counties in New Jersey (NJ) from 2003 through 2012, which has been 
described in detail elsewhere [26-28]. Breast cancer cases in NYC were ascertained through 
12 targeted hospitals and cases from NJ were identified through the NJ State Cancer 
Registry of the Department of Health through rapid case ascertainment. Eligible cases 
included English-speaking women who self-identified as AA or EA, 20 to 75 years of age, 
with a primary, newly diagnosed, histologically confirmed breast cancer. Controls without a 
history of any cancer diagnosis other than non-melanoma skin cancer were identified 
through random digit dialing (RDD) of residential telephone numbers and frequency 
matched by telephone prefixes of cases, a commonly accepted method for selecting controls 
in targeted areas to assemble a population comparable to cases [26-28]. The majority of 
cases were interviewed within 6 months of diagnosis, but were asked about behaviors prior 
to breast cancer diagnosis. In addition to recruitment by RDD, controls in NJ were also 
recruited through community-based efforts, mainly through churches and health events, with 
the help of community partners and advocates [28]. Community controls were on average 
less educated, had lower income, and were more likely to have Medicaid or Medicare as a 
form of insurance compared to RDD controls. Using data obtained by the American 
Community Survey of the United States Census Bureau, we showed within our study sample 
that a combination of controls recruited by RDD and from the community were more 
representative of the general AA community in New Jersey regarding education, income, 
marital status, and level of obesity, as an indicator of lifestyle factors, than RDD controls 
alone [28] and were a better comparison group to population-based cases recruited in NJ. 
Controls identified by RDD and community-based controls were frequency-matched to 
cases by self-reported race and 5-year age categories. In-person interviews were conducted 
to query participants on potential breast cancer risk factors and socioeconomic factors, 
including type of medical insurance and screening habits, and detailed anthropometric 
measurements were taken [28]. A signed release to obtain pathology data and tumor blocks 
was part of the informed consent process for cases, and data on hormone receptors, 
histology, grade and stage were abstracted from pathology reports by trained study staff. 
Protocols for agreement to participate and informed consent were approved by the 
Institutional Review Boards at Roswell Park Cancer Institute (RPCI), Rutgers Cancer 
Institute of New Jersey (CINJ), Icahn School of Medicine at Mount Sinai School (ISMMSS; 
formerly the Mount Sinai School of Medicine) and the participating hospitals in NYC in 
compliance with the Declaration of Helsinki.
Out of a total of 1,513 women with breast cancer in the WCHS, women were excluded if 
they were diagnosed with pure DCIS (n=258), invasive carcinomas of other types (n=141), 
or cancers with unknown histology (n=283, 53 cases of which were excluded because 
presence or absence of DCIS with IDC could not be determined). Records of pure IDC 
patients were included only when medical reports clearly stated that there was no DCIS 
component, or included detailed descriptions of hyperplasia without mention of DCIS. In 
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addition, slides of tumor samples from cases were reviewed by two breast pathologists to 
verify presence or absence of DCIS. Included in the final study were 831 women with IDC 
(recognized as ductal carcinoma of no special type in accordance with World Health 
Organization terminology) or mixed IDC/invasive lobular carcinoma and 1,620 controls.
Statistical Analyses
Differences between controls, and cases with pure IDC or mixed IDC/DCIS were compared 
using Student's t-test for continuous variables and chi-squared tests for categorical variables. 
Odds ratios (ORs) and corresponding 95% confidence intervals (CIs) and p-values were 
calculated to estimate associations between risk factors and mixed IDC/DCIS or pure IDC in 
case-control multivariable models using unconditional logistic regression. Analyses were 
conducted for AA and EA women combined, which included adjustments for self-reported 
race. Potential interactions by race were also assessed by introducing cross-product terms 
(race x exposure) into the logistic regression model for all women combined. Case-case 
analyses, using unconditional logistic regression, were performed to determine if risk factors 
were differentially associated with odds of being diagnosed with pure IDC (“case”) 
compared to odds of being diagnosed with mixed IDC/DCIS (“control”). Since AA women 
are more likely to be diagnosed with more aggressive breast cancers compared to EA 
women, and risk factors for breast cancer may have differential effects in EA and AA 
women [29-31], case-case findings were also stratified by self-reported race to determine if 
observed associations are modified by race. Wald's Chi-square was used to calculate p-
values for categorical variables. P-trends were calculated using median values for each 
category or quantile.
Risk factors evaluated included family history, defined as having a first degree relative with 
breast cancer, age at menarche, parity, oral contraceptive (OC) use, menopausal hormone 
therapy (MHT) use, current BMI, smoking, age at first birth, age at last birth, number of 
births, and total breastfeeding duration. Categories for duration of OC use (1-72 months, > 
72 months) were defined by months of use associated with increased breast cancer risk in 
this and previous studies [32]. Categories of age at first and last birth were created using 
cutoffs from previous literature [29, 30] that allowed for adequate sample sizes within both 
AA and EA groups, since AA women were more likely to have earlier age at first birth as 
well as earlier age at last birth. ORs estimating associations with age at first birth, age at last 
birth, number of births and breastfeeding were calculated among parous women only. BMI 
was calculated as kg/m2, using weight and height measurements collected during home 
interviews. Categories of <25, 25 to <30, and ≥30 kg/m2 were chosen for BMI, 
corresponding to normal and underweight, overweight, and obesity, respectively. 
Underweight women were included in the analyses, but were not considered as a separate 
category due to their small number. Data were stratified by menopausal status for 
examination of BMI due to differential effects of BMI on pre- and postmenopausal breast 
cancer risk in previous studies [28]. Women were considered premenopausal if they had 
either periods within the last year or at least one remaining ovary and were under the age of 
50, the median age for natural menopause in the WCHS. Otherwise, women without periods 
within the last year were considered postmenopausal. Multivariable analyses were 
performed to account for potential confounding factors selected a priori. Models were 
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adjusted for age, race, birthplace, family history, education, OC use, age at menarche, parity 
and menopausal status (unless they were the main variable of interest), given their known 
associations with breast cancer risk and/or reproductive history. Place of birth was included 
in our models because women born outside of the United States tended to have more 
children, were more likely to have breastfed, and were more likely to be diagnosed with 
more aggressive disease compared to women born in the United States. Because less 
frequent screening may lead to the detection of more advanced lesions, and because the 
identification of a DCIS component may be inversely associated with later stage disease, we 
also adjusted for screening history using a composite screening score. The score was based 
on responses to three questions: 1) whether the participant had ever had a physician breast 
examination, 2) had self-examined breasts for lumps, or 3) had ever received a 
mammogram. Each screening measure was assigned 1 point, for a score of 3 for a woman 
who reported ever using all 3 screening measures. Age at first birth was included when 
factors associated with reproduction were assessed, and self-reported race was included 
when AA and EA women were combined. In case-case analyses between pure IDC and 
mixed IDC/DCIS, a third model with additional adjustments for ER status is shown since 
pure IDC was strongly associated with ER negative cancers in our study population.
Additional case-case analyses comparing tumor characteristics of pure IDC and mixed IDC/
DCIS were conducted using unconditional logistic regression. Variables describing tumor 
characteristics included age, tumor size, tumor grade, stage, lymph node (LN) status, 
lymphovascular invasion (LVI), ER status, progesterone (PR) status, HER2 status and 
method of breast cancer discovery. Models were adjusted as described above for case-
control analyses.
Breast cancer subtypes were approximated from ER, PR and HER2 status. Tumors with 
positive ER or PR status were categorized as luminal A or B, depending on negative or 
positive HER2 status, respectively. Tumors with a negative ER and PR status were 
categorized as triple negative or HER2 overexpressing breast cancer, depending on negative 
or positive HER2 status, respectively.
Sensitivity analyses were conducted to examine proportions of pure IDC and mixed IDC/
DCIS across different hospitals to determine if reporting of pure IDC and mixed IDC/DCIS 
varied between institutions. The potential impact of heterogeneity across institutions on risk 
estimates were assessed by removing cases from each specific hospital, in turn, to determine 
if associations were affected. All analyses were performed using SAS 9.2.
Results
Characteristics of women with breast cancer according to pure IDC and mixed IDC/DCIS, 
as well as controls, are shown in Table 1, along with unadjusted odds ratios (OR) and 95% 
confidence intervals (CI) for developing pure IDC and mixed IDC/DCIS. Women with pure 
IDC constituted 21.8% of women with invasive breast cancer. Sixty-three percent of women 
with pure IDC were AA, compared to 53.5% of women with mixed IDC/DCIS (P=0.05). 
Women with pure IDC were more likely to have a high school education or less (43% pure 
IDC vs. 33% mixed IDC/DCIS, P=0.02).
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Case-control associations with breast cancer risk factors
Case-control comparisons are shown for pure IDC and mixed IDC/DCIS in Table 2. Overall, 
women with a family history of breast cancer had greater odds of being diagnosed with pure 
IDC (OR=1.54; 95% CI, 1.02-2.34) or mixed IDC/DCIS (OR=1.44; 95% CI, 1.12-1.85) 
compared to those without a family history. OC use was associated with increased odds of 
mixed IDC/DCIS compared to nonusers (OR=1.30; 95% CI, 1.02-1.66 for over 72 months 
of OC use; p-trend=0.03), with a similar, but non-significant associations and trend for pure 
IDC (OR=1.36; 95% CI, 0.91-2.05 for over 72 months of OC use; p-trend=0.16). 
Postmenopausal women with BMI ≥ 30 compared to those with BMI <25 kg/m2 had a 
reduced risk of pure IDC (OR=0.35; 95% CI, 0.18-0.67; p-trend=0.02), but no associations 
were observed with mixed IDC/DCIS (p-trend=0.58). Women with last birth later than age 
33 also had reduced risk of pure IDC (OR=0.59; 95% CI, 0.37-0.93; p-trend=0.04), but not 
mixed IDC/DCIS (OR=0.85; 95% CI, 0.65-1.10), compared to women who had their last 
birth by age 22. There was some indication that women who had breastfed 12 months or 
longer were less likely to be diagnosed with pure IDC compared to women who did not 
breastfeed (p-trend=0.07). No associations, however, were observed between breast feeding 
and risk of being diagnosed with mixed IDC/DCIS (p-trend=0.49). There was some 
indication that risk of pure IDC or mixed IDC/DCIS may differ by race for OC use, BMI 
among postmenopausal women, parity, and age at last birth. In fully adjusted models, risk of 
pure IDC was greater with OC use over 72 months among AA women (OR=1.75; 95% CI, 
1.05-2.92), but not among EA women (OR=0.99; 95% CI, 0.51-1.95; p-interaction = 0.18) 
(See Supplementary Table 1). Odds of mixed IDC/DCIS was similarly increased with longer 
OC use among AA women (OR=1.69; 95% CI, 1.21-2.36), but not among EA women 
(OR=0.96; 95% CI, 0.67-1.38; p-interaction=0.02) (See Supplementary Table 2). Among 
postmenopausal women, higher BMI was found to be protective for pure IDC only among 
AA women (≥30 vs < 25 kg/m2, OR=0.22; 95% CI, 0.10-0.51; p-interaction = 0.08). There 
was some indication that increasing parity was protective for pure IDC (OR=0.46; 95% CI, 
0.21-1.01; p-interaction =0.24) and mixed IDC/DCIS (OR=0.61; 95% CI, 0.40-0.93; p-
interaction=0.82) among EA women, but not among AA women, and older age at last birth 
was protective for pure IDC, but only among AA women (> 33 vs ≤ 28 years, OR=0.48; 
95% CI, 0.28-0.85; p-interaction = 0.24).
Case-case associations with breast cancer risk factors
Case-case analyses comparing pure IDC to mixed IDC/DCIS as the “control” group are 
shown in Table 3. EA women were less likely to be diagnosed with pure IDC compared to 
mixed IDC/DCIS in the age-adjusted model (OR=0.72; 95% CI, 0.52-1.01), however, this 
association was null in the fully-adjusted model, largely attributable to additional adjustment 
for ER status (OR=1.07; 95% CI, 0.67-1.72, Model 3). Postmenopausal women with BMI ≥ 
30 kg/m2 were less likely to be diagnosed with pure IDC than mixed IDC/DCIS (OR=0.38; 
95% CI, 0.19-0.79; p-trend=0.01) compared to women with BMI < 25 kg/m2. Women who 
were current or former smokers were less likely to be diagnosed with pure IDC than mixed 
IDC/DCIS (OR=0.68; 95% CI, 0.45-1.01), however, this association was only of borderline 
significance. Women who breastfed up to 12 months (OR=0.55; 95% CI, 0.32-0.94) or 
longer (OR=0.47; 95% CI, 0.36-0.87) were approximately 50% less likely to be diagnosed 
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with pure IDC than with mixed IDC/DCIS (p-trend=0.18) compared to women who did not 
breastfeed.
We additionally compared case-case associations stratified by race to see if risk factors were 
similarly associated in both AA and EA populations (Table 4). Among AAs, 
postmenopausal women with BMI >30 kg/m2 showed significantly reduced odds of pure 
IDC (OR=0.33; 95% CI, 0.13-0.86) compared to those with BMI ≤25 kg/m2; no differences 
were observed among EA women. ORs below unity were also observed among EA women 
who breastfed up to 12 months (OR=0.34; 95% CI, 0.14-0.84) or longer (OR=0.37; 95% CI, 
0.14-1.03) compared to women who did not breastfeed (p-trend=0.25), with similar, but 
non-significant findings among AA women. Race-stratified analyses were limited by small 
sample size, particularly among EA women, with only 67 cases of pure IDC. Interactions 
with race were not observed in case-case analyses.
Case-case associations with tumor characteristics
When associations with tumor characteristics were examined, tumors larger than 2 cm were 
more likely to be pure IDC than mixed IDC/DCIS (OR=1.58; 95% CI, 1.07- 2.35 for tumors 
2 to <5 cm; OR= 2.16; 95% CI, 1.00-4.67 for tumors ≥ 5 cm) (Table 5). In addition to tumor 
size, ER negative tumors were also associated with increased odds of pure IDC (OR=2.79; 
95% CI, 1.93-4.05), while positive LN status (OR=0.55; 95% CI, 0.35-0.87) and LVI 
(OR=0.58; 95% CI, 0.36-0.92) were associated with reduced odds of pure IDC. Triple 
negative tumors were over 3 times more likely to be pure IDC than mixed IDC/DCIS 
(OR=3.26; 95% CI, 2.08-5.12). Tumors discovered by palpation rather than mammogram 
were more likely to be pure IDC than mixed IDC/DCIS (OR=1.54; 95% CI, 1.02-2.32). A 
significant interaction between race and tumor grade in association with pure IDC was 
observed; EA women with higher grade tumors were more likely to have pure IDC 
(OR=3.94; 95% CI, 1.32-11.7), whereas higher grade was not associated with pure IDC 
among AA women (OR=1.38; 95% CI, 0.81-2.37; p-interaction=0.02) (Data not shown).
Case-case risk factor associations stratified by ER status
When stratified by ER status (Supplementary Table 3), reduced odds of being diagnosed 
with pure IDC compared to mixed IDC/DCIS were noted for ER negative breast cancers 
among postmenopausal women with BMI≥30 compared to women with BMI<25. Greater 
time spent breastfeeding was similarly associated with lower odds of pure IDC among 
women with ER positive and ER negative breast cancers. Associations, however, were not 
statistically significant for EA women, likely due in part to sample size limitations. 
Interactions by ER status were not statistically significant.
Discussion
There are few reported studies in the literature investigating potential differences between 
pure IDC and mixed IDC/DCIS for invasive breast cancers [2, 6-9, 11, 17]. We 
hypothesized that risk factors for pure IDC may differ from those for mixed IDC/DCIS if 
these cancers are biologically distinct from one another [6]. Identification of a distinct risk 
factor profile for pure IDC could target women who should be more closely screened to 
Ruszczyk et al. Page 8













prevent pure IDC tumors, which have been shown to be associated with poorer prognosis 
than mixed IDC/DCIS [6-11]. To our knowledge, this is the first study to examine risk 
factors associated with pure IDC versus mixed IDC/DCIS. In this case-control study of 
breast cancer in AA and EA women, we found that higher BMI among postmenopausal 
women, older age at last birth, and longer duration of breastfeeding among parous women 
were protective for pure IDC, but not for mixed IDC/DCIS.
Demographic characteristics differed between pure IDC and mixed IDC/DCIS as well. 
Women with more education, and more extensive history of breast cancer screening were 
less likely to have pure IDC than mixed IDC/DCIS. This is similar to findings for women 
with ER negative breast cancer compared to women with ER positive breast cancer, who 
were found to have attained less education and were screened less often [33]. Likewise, 
Starks et al. found that breast cancer patients with p53 mutations were more likely to have 
lower incomes, and suggested that a lifetime of exposures associated with socioeconomic 
status might result in different breast cancer etiologies [34]. To reduce potential bias 
resulting from an association between later detection and pure IDC diagnosis, we adjusted 
our models for screening history and education level.
Tumor characteristics differed between pure IDC and mixed IDC/DCIS in this and previous 
studies [5-6, 10]. Pure IDC cases were not only more likely to be ER negative, but women 
with pure IDC were also less likely to have lymph node involvement or LVI. Previous 
studies have found pure IDC tumors to have higher Ki-67 expression [6], fewer associated 
calcifications [10], and a greater likelihood of being an interval breast cancer [5]. Pure IDC 
may show tumor characteristics associated with a fast-growing tumor etiology, with fewer 
cases of lymph node involvement among women with less education and possibly lower 
socioeconomic status.
Postmenopausal women with normal or lower BMIs were more likely to be diagnosed with 
pure IDC than mixed IDC/DCIS in our study. After menopause, when estrogen is no longer 
produced by the ovaries, adipose tissue is the depot for conversion of androgens to estrogens 
through aromatase activity [36-37]. Estrogens are known to be related to breast cancer risk, 
and it is thought that higher risk with greater BMI in postmenopausal women is mediated 
through this mechanism [38]. Most studies show a greater association between risk and BMI 
among women with ER positive breast cancer [39-42], although there are studies with 
discrepant findings [35, 43-44]. There were no associations observed between mixed IDC/
DCIS and BMI in this study. In case-control analyses, we found that higher BMI among 
postmenopausal women was unexpectedly associated with decreased odds of pure IDC, 
which is in contrast to previous studies looking at all breast cancers combined[38], 
suggesting that pure IDC may represent a subset of breast cancer with unique risk factors. A 
decreased risk of overall invasive breast cancer was observed among postmenopausal AA 
women with BMI≥25 in the Black Women's Health Study, similar to the decreased risk for 
pure IDC observed among postmenopausal AA women in our study [44]. It is known that 
BMI influences metabolic pathways [45] and subsequently may influence cancer 
development and progression [46]. In one follow-up study of 2,092 breast cancer survivors, 
women with metabolic syndrome were twice as likely to experience distant metastasis [47]. 
It is possible that BMI measured at baseline might have been affected by breast cancer 
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treatment since home interviews with anthropometric measurements were conducted 
approximately 6 months after diagnosis. Potential bias from the effect of treatment on BMI, 
however, cannot explain the different estimates found between pre- and postmenopausal 
women.
We observed an inverse association between breastfeeding and pure IDC compared to mixed 
IDC/DCIS. Breastfeeding appears to be modestly protective for breast cancer [48-50], but 
seems to be substantially more protective against the more aggressive breast cancer 
subtypes, including hormone-receptor negative and basal-like cancers in most [29, 51-54], 
but not all studies [30, 55]. Mechanisms postulated for these effects include the reduction of 
ovulatory cycles, induction of breast differentiation, and the presence of human milk 
complex of alpha-lactalbumin and oleic acid (HAMLET) secreted in milk that causes tumor 
cells to undergo apoptosis [56-60]. Women with an older age at last birth also had reduced 
odds of pure IDC, contrary to the noted increase in breast cancer risk in women up to 10 
years after pregnancy [61]. More studies are needed to examine reproductive factors 
associated with breast cancer in AA women compared to EA women.
Previous studies describe an association between ER negative breast cancer and pure IDC 
[6, 11]. Because pure IDC tumors are more likely to be ER negative, the observed 
association between breastfeeding and reduced odds of pure IDC in relation to mixed IDC 
may be similar to previous studies showing a greater protective effect of breastfeeding 
against ER negative tumors [29, 51-54]. However, despite the strong association of pure 
IDC with negative ER status, observations after stratification by ER status indicated that the 
association between longer duration of breastfeeding and reduced risk of pure IDC did not 
depend upon ER status, and therefore unlikely to be mediated by estrogen-related pathways.
AA breast cancer patients present more often than EA patients with positive LNs and tumors 
that are larger, higher grade, ER negative, and later stage, i.e. characteristics associated with 
a poor prognosis [62-66]. Because disease characteristics associated with pure IDC are also 
more common in AA women, the presence or absence of a DCIS component may reflect a 
distinct natural history that could account for some of the differences observed between AA 
and EA patients. In our study, AA women with breast cancer were more likely to have pure 
IDC than mixed IDC/DCIS, but observed associations between breast cancer risk factors and 
risk of pure IDC or mixed IDC/DCIS, with the exception of OC use, BMI among 
postmenopausal women, parity, and age at last birth, were not found to be differential by 
race. Once adjustment for demographic and breast cancer risk factors were added to the 
model, however, the increased odds of pure IDC among AA women was attenuated, 
suggesting that the development of pure IDC versus mixed IDC/DCIS is related, in part, to 
different risk factor and demographic profiles. The higher occurrence of pure IDC due to 
these factors may account for some of the disparities observed in breast cancer 
characteristics between AA and EA women.
Strengths of this study include the large number of participants and extensive information 
provided by in-person interviews, pathology reports and tumor samples available in the 
WCHS, allowing for the examination of several risk factors and tumor characteristics with 
adjustment for potential confounders. Rarer forms of breast cancer were not included and 
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cases were limited to invasive tumors with ductal histology so that analyses could be 
focused on a set of tumors with more similar etiologies and prognosis. Finally, this is the 
first study of our knowledge that has examined the association of breast cancer risk factors 
and the presence or absence of an in situ component concomitant to invasive carcinoma, 
which could affect disease prognosis. In addition, we had the benefit of looking at 
associations within AA and EA women.
Several potential limitations should be noted when interpreting this data. First, missing data 
on the histology of breast tumors led to the exclusion of 30% of cases from our analyses, 
which could have biased our findings if records between pure IDC and mixed IDC/DCIS 
were differentially or systematically missing from a group of women that shared similar risk 
factors. We compared tumor characteristics and risk factors between WCHS participants 
with and without missing histologies and found no significant differences. ER status, tumor 
size, breastfeeding and BMI in women with missing tumor histologies were intermediate 
between women with pure IDC and mixed IDC/DCIS, suggesting a similar proportion of 
women with missing data among women with pure IDC and mixed IDC/DCIS. Secondly, 
lack of standardization of pathology reports collected from a number of different hospitals 
may have introduced misclassification, possibly attenuating associations if misclassifications 
were non-differential across our variables of interest. Analyses of pure IDC and mixed IDC/
DCIS diagnoses at individual hospitals did not identify any significant differences in the 
proportion of pure IDC to mixed IDC/DCIS to indicate reporting biases stemming from 
pathology reports. Additionally, two breast pathologists reviewed selected slides from 
registered cases to verify the presence or absence of DCIS. Some hospitals did report greater 
numbers of women with negative ER status, which may reflect possible differences in the 
reporting of ER status or true underlying differences in the patient populations served. 
Finally, bias may have been introduced with earlier detection of mixed IDC/DCIS compared 
to pure IDC if women with mixed IDC/DCIS are more likely to obtain screening 
mammography. Women with pure IDC, who tend to be less educated, may have lower 
access to screening and present at a later disease stage with larger cancers, although this 
does not explain why women with pure IDC were less likely to have positive lymph node 
status. To reduce potential bias resulting from screening, we included a screening score in 
our models and adjusted for education, although residual confounding may still have 
occurred since the score only contained information on ever screening behavior rather than 
screening behavior close in time to the cancer diagnosis.
Conclusions
In conclusion, breast cancer has been described as a heterogeneous disease based upon a 
range of genetic factors, molecular profiles, and clinical manifestations. The presence or 
absence of a DCIS component, a tumor characteristic associated with breast cancer 
outcomes, may represent different etiologic pathways for breast cancer. Some risk factors 
varied significantly between cases with pure IDC and mixed IDC/DCIS. Although a portion 
of pure IDC cancers may have progressed from mixed IDC/DCIS cancers, the absence of a 
DCIS component may also represent a tumor type with a distinctive developmental pathway, 
associated with lower BMI in postmenopausal women and shorter breastfeeding duration. 
These findings need to be confirmed in a larger study. Understanding of modifiable risk 
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factors associated with reduced risk of pure IDC can potentially be applied to preventing this 
breast cancer subtype.
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Table 1
Characteristics of breast cancer cases and controls in the WCHS, (n=2,451)
Characteristics Controls Pure IDC Unadjusted OR 
(95% CI) for 
developing pure 
IDC
Mixed IDC/DCIS Unadjusted OR 




case OR (95% 
CI) for 
developing pure 













    Pre 867 (53.5) 101 (55.8) 1.00 338 (52.0) 1.00 1.00
    Post 753 (46.5) 80 (44.2) 0.91 (0.67, 1.24) 312 (48.0) 1.06 (0.89, 1.27) 0.86 (0.62, 1.20)
Race (N, %)
    AA 905 (55.9) 114 (63.0) 1.00 348 (53.5) 1.00
1.00
c
    EA 715 (44.1) 67 (37.0) 0.75 (0.54, 1.02) 302 (46.5) 1.10 (0.92, 1.32) 0.68 (0.48, 0.95)
Education (N, %)







    Some college 394 (24.3) 43 (23.8) 0.61 (0.41, 0.90) 154 (23.7) 0.80 (0.63, 1.03) 0.76 (0.49, 1.16)
    College graduate 794 (49.0) 60 (33.1) 0.42 (0.29, 0.60) 285 (43.8) 0.74 (0.59, 0.91) 0.57 (0.39, 0.83)
Birthplace (N, %)





    Caribbean 133 (8.2) 33 (18.2) 2.58 (1.69, 2.34) 86 (13.3) 1.75 (1.31, 2.34) 1.47 (0.94, 2.30)
    Other 135 (8.3) 18 (9.9) 1.39 (0.82, 2.34) 65 (10.0) 1.30 (0.95, 1.78) 1.06 (0.61, 1.86)
Composite screening 
score (N, %)
    0+1 110 (6.8) 25 (13.8)
1.00
a 60 (9.2) 1.00 1.00
    2 535 (33.0) 56 (30.9) 0.46 (0.28, 0.77) 194 (29.9) 0.67 (0.47, 0.95) 0.69 (0.40, 1.20)
    3 975 (60.2) 100 (55.3) 0.45 (0.28, 0.73) 395 (60.9) 0.74 (0.53, 1.04) 0.61 (0.36, 1.02)
Abbreviations: WCHS, Women's Circle of Health Study; IDC, invasive ductal carcinoma; DCIS, ductal carcinoma in situ; OR, Odds ratio; CI, 
confidence intervals; SD, standard deviation; AA, African American; EA, European American P-values from Student's t-test for continuous 
variables, and from Chi-squared tests for categorical variables
a
P ≤ 0.05 for comparison of pure IDC versus controls
b
P ≤ 0.05 for comparison of mixed IDC versus controls
c
P ≤ 0.05 for comparison of pure IDC vs versus mixed IDC/DCIS
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Table 2














    No 1,395 (86.2) 147 (81.2) 1.00 526 (80.9) 1.00
    Yes 224 (13.8) 34 (18.8) 1.54 (1.02, 2.34) 124 (19.1) 1.44 (1.12, 1.85)
P=0.04 P=0.004
Age at menarche (yrs)
    ≥14 420 (26.0) 45 (24.9) 1.00 180 (28.0) 1.00
    12 to 13 784 (48.7) 80 (44.2) 1.03 (0.70, 1.53) 316 (49.2) 1.12 (0.89, 1.42)
    <12 407 (25.3) 56 (30.9) 1.39 (0.90, 2.13) 146 (22.8) 1.23 (0.95, 1.60)
P-trend=0.13 P-trend=0.12
OC use (mos)
    0 604 (37.3) 74 (40.9) 1.00 242 (37.3) 1.00
    1 to 72 608 (37.6) 58 (32.0) 1.00 (0.69, 1.46) 232 (35.7) 1.12 (0.89, 1.40)
    >72 407 (25.1) 49 (27.0) 1.36 (0.91, 2.05) 175 (27.0) 1.30 (1.02, 1.66)
P-trend=0.16 P-trend=0.03
Postmenopausal MHT use
    No 516 (68.5) 51 (63.8) 1.00 212 (67.9) 1.00
    Yes 237 (31.5) 29 (36.2) 1.37 (0.80, 2.35) 100 (32.1) 0.99 (0.73, 1.35)
P=0.25 P=0.94
Current BMI (kg/m2), Premenopausal
    <25 297 (34.6) 31 (31.0) 1.00 115 (34.8) 1.00
    25 to <30 231 (26.9) 24 (24.0) 0.77 (0.43, 1.39) 100 (30.3) 1.12 (0.80, 1.57)
    ≥30 331 (38.5) 45 (45.0) 0.99 (0.58, 1.69) 115 (34.8) 0.90 (0.64, 1.27)
P-trend=0.68 P-trend=0.77
Current BMI (kg/m2), Postmenopausal
    <25 184 (25.0) 27 (36.5) 1.00 71 (23.3) 1.00
    25 to <30 216 (29.3) 23 (31.1) 0.66 (0.35, 1.23) 86 (28.2) 1.08 (0.73, 1.60)
    ≥30 337 (45.7) 24 (32.4) 0.35 (0.18, 0.67) 148 (48.5) 1.08 (0.75, 1.57)
P-trend=0.02 P-trend=0.58
Smoking
    No 909 (56.1) 113 (62.4) 1.00 365 (56.1) 1.00
    Current/Former 711 (43.9) 68 (37.6) 0.76 (0.54, 1.07) 285 (43.9) 1.01 (0.83, 1.23)
P=0.11 P=0.91
Parity
    0 348 (21.6) 38 (21.0) 1.00 150 (23.4) 1.00
    1 343 (21.3) 31 (17.1) 0.70 (0.42, 1.17) 132 (20.6) 0.86 (0.64, 1.14)
    2 469 (29.1) 60 (33.2) 0.98 (0.63, 1.52) 185 (28.9) 0.83 (0.64, 1.08)
    ≥3 450 (28.0) 52 (28.7) 0.67 (0.41, 1.07) 174 (27.2) 0.72 (0.55, 0.96)



























Age at first birth (yrs)
b
    ≤22 558 (44.0) 68 (47.5) 1.00 225 (45.2) 1.00
    >22 to ≤30 409 (32.3) 54 (37.8) 1.58 (1.02, 2.44) 175 (35.1) 1.14 (0.87, 1.50)
    >30 301 (23.7) 21 (14.7) 0.93 (0.52, 1.65) 98 (19.7) 0.92 (0.66, 1.28)
P-trend=0.84 P-trend=0.66
Age at last birth (yrs)
c
    ≤28 454 (35.8) 66 (46.1) 1.00 189 (38.0) 1.00
    >28 to ≤33 356 (28.1) 41 (28.7) 0.89 (0.57, 1.37) 146 (29.3) 0.98 (0.74, 1.28)




    None 547 (43.1) 75 (52.4) 1.00 213 (42.7) 1.00
    >0-12 402 (31.6) 40 (28.0) 0.76 (0.49, 1.19) 171 (34.3) 1.15 (0.88, 1.50)
    >12 321 (25.3) 28 (19.6) 0.61 (0.37, 1.02) 115 (23.0) 0.94 (0.70, 1.27)
P-trend=0.07 P-trend=0.49
Abbreviations: IDC, invasive ductal carcinoma; DCIS, ductal carcinoma in situ; WCHS, Women's Circle of Health Study; OR, Odds Ratio; CI, 
confidence interval; AA, African American; EA, European American; OC, oral contraceptive; MHT, menstrual hormone therapy; BMI, body mass 
index
a
Unconditional logistic regression models were used to estimate ORs and 95% CIs. All models were adjusted for age, race, birthplace, family 
history, composite screening score, education, OC use, age at menarche, parity and menopausal status. All associations were adjusted for covariates 
listed above unless the covariate was the main exposure of interest or was used as a stratification variable (menopausal status for BMI and MHT 
use).
b
Among 1,912 parous women only
c
Among 1,912 parous women only, with an additional adjustment for age at first birth
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Table 3
Case-case comparison of risk factors for pure IDC vs mixed IDC/DCIS in the WCHS (n=831)
Pure IDC Mixed IDC/DCIS
Model 1 Age-adjusted 
OR (95% CI)
a
Model 2 Fully 
adjusted OR (95% 
CI)
a
Model 3 Fully 







    AA 114 (63.0) 348 (53.5) 1.00 1.00 1.00
    EA 67 (37.0) 302 (46.5) 0.72 (0.52, 1.01) 0.82 (0.55, 1.20) 1.07 (0.67, 1.72)
P=0.05 P=0.30 P=0.78
Family history
    No 147 (81.2) 526 (80.9) 1.00 1.00 1.00
    Yes 34 (18.8) 124 (19.1) 0.99 (0.65, 1.51) 1.04 (0.67, 1.60) 1.07 (0.67, 1.72)
P=0.70 P=0.87 P=0.78
Age at menarche (yrs)
    ≥14 56 (30.9) 180 (28.0) 1.00 1.00 1.00
    12 to 13 80 (44.2) 316 (49.2) 0.82 (0.54, 1.24) 0.90 (0.59, 1.38) 0.92 (0.57, 1.47)
    <12 45 (24.9) 146 (22.7) 1.01 (0.64, 1.58) 1.06 (0.67, 1.67) 1.18 (0.71, 1.97)
P-trend=0.90 P-trend=0.77 P-trend=0.46
OC use (mos)
    0 74 (40.9) 242 (37.3) 1.00 1.00 1.00
    1 to 72 58 (32.0) 232 (35.8) 0.79 (0.54, 1.18) 0.86 (0.58, 1.29) 0.89 (0.57, 1.37)
    >72 49 (27.1) 175 (27.0) 0.87 (0.57, 1.33) 0.98 (0.63, 1.51) 0.88 (0.54, 1.43)
P-trend=0.46 P-trend=0.58 P-trend=0.88
Postmenopausal MHT use
    No 51 (63.8) 212 (68.0) 1.00 1.00 1.00
    Yes 29 (36.3) 100 (32.1) 1.21 (0.72, 2.03) 1.38 (0.80, 2.38) 1.41 (0.78, 2.56)
P=0.64 P=0.25 P=0.26
Current BMI (kg/m2), Premenopausal
    <25 31 (31.0) 115 (34.9) 1.00 1.00 1.00
    25 to <30 24 (24.0) 100 (30.3) 0.89 (0.49, 1.62) 0.73 (0.39, 1.37) 0.59 (0.29, 1.20)
    ≥30 45 (45.0) 115 (34.9) 1.45 (0.85, 2.46) 1.01 (0.54, 1.89) 0.89 (0.45, 1.78)
P-trend=0.10 P-trend=0.76 P-trend=0.58
Current BMI (kg/m2), Postmenopausal
    <25 27 (36.5) 71 (23.3) 1.00 1.00 1.00
    25 to <30 23 (31.1) 86 (28.2) 0.70 (0.37, 1.33) 0.65 (0.33, 1.27) 0.73 (0.35, 1.51)
    ≥30 24 (32.4) 148 (48.5) 0.42 (0.23, 0.79) 0.36 (0.19, 0.70) 0.38 (0.19, 0.79)
P-trend=0.03 P-trend=0.003 P-trend=0.01
Smoking
    No 113 (62.4) 365 (53.2) 1.00 1.00 1.00
    Current/Former 68 (37.6) 285 (43.9) 0.78 (0.56, 1.10) 0.77 (0.53, 1.11) 0.68 (0.45, 1.01)
P=0.16 P=0.15 P=0.06
Parity
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Pure IDC Mixed IDC/DCIS
Model 1 Age-adjusted 
OR (95% CI)
a
Model 2 Fully 
adjusted OR (95% 
CI)
a
Model 3 Fully 






    0 38 (21.0) 151 (23.2) 1.00 1.00 1.00
    1 31 (17.1) 133 (20.5) 0.93 (0.55, 1.57) 0.82 (0.48, 1.40) 0.80 (0.43, 1.46)
    2 60 (33.2) 190 (29.2) 1.27 (0.80, 2.01) 1.17 (0.73, 1.88) 1.11 (0.66, 1.87)
    ≥3 52 (28.7) 176 (27.1) 1.21 (0.75, 1.94) 0.92 (0.56, 1.53) 0.74 (0.42, 1.31)
P-trend=0.26 P-trend=0.88 P-trend=0.56
Age at first birth (yrs)
b
    ≤22 68 (47.5) 225 (45.2) 1.00 1.00 1.00
    >22 to ≤30 54 (37.8) 175 (35.1) 1.01 (0.67, 1.53) 1.37 (0.86, 2.16) 1.43 (0.86, 2.36)
    >30 21 (14.7) 98 (19.7) 0.69 (0.40, 1.19) 1.11 (0.59, 2.08) 1.33 (0.65, 2.70)
P-trend=0.23 P-trend=0.56 P-trend=0.66
Age at last birth (yrs)
c
    ≤28 66 (46.1) 189 (38.0) 1.00 1.00 1.00
    >28 to ≤33 41 (28.7) 146 (29.3) 0.80 (0.51, 1.24) 0.81 (0.49, 1.32) 0.77 (0.45, 1.31)




    None 75 (52.4) 213 (42.7) 1.00 1.00 1.00
    >0-12 40 (28.0) 171 (34.3) 0.63 (0.40, 0.97) 0.62 (0.39, 1.01) 0.55 (0.32, 0.94)
    >12 28 (19.6) 115 (23.0) 0.64 (0.39, 1.05) 0.58 (0.34, 1.01) 0.47 (0.36, 0.87)
P-trend=0.14 P-trend=0.11 P-trend=0.18
Abbreviations: IDC, invasive ductal carcinoma; DCIS, ductal carcinoma in situ; WCHS, Women's Circle of Health Study; OR, Odds Ratio; CI, 
confidence interval; AA, African American; EA, European American; OC, oral contraceptive; MHT, menstrual hormone therapy; BMI, body mass 
index
Model 1 was adjusted for age only.
Model 2 was adjusted for age, race, birthplace, family history, composite screening score, education, OC use, age at menarche, parity and 
menopausal status.
Model 3 was adjusted for all variables in Model 2 with the addition of ER status.
All associations were adjusted for covariates listed above unless the covariate was the main exposure of interest or was used as a stratification 
variable (menopausal status for BMI and MHT use).
a
Unconditional logistic regression models were used to estimate ORs and 95% CIs.
b
Among 642 parous women only
c
Among 642 parous women only, with an additional adjustment for age at first birth
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Table 4
Associations between breast cancer risk factors and odds of pure IDC compared to mixed IDC/DCIS, by AA 
and EA race, in the Women's Circle of Health Study, (N=755)
AA EA
Pure IDC Mixed IDC/DCIS OR (95% CI)











    <45 35 (32.4) 97 (30.6) 0.88 (0.47, 1.67) 17 (25.4) 67 (25.5) 0.93 (0.43, 2.03)
    ≥45 73 (67.6) 220 (69.4) 1.00 50 (74.6) 196 (74.5) 1.00
P=0.70 P=0.86
Family history
    No 94 (87.0) 271 (85.5) 1.00 48 (71.6) 198 (75.3) 1.00
    Yes 14 (13.0) 46 (14.5) 0.84 (0.42, 1.67) 19 (28.4) 65 (24.7) 1.17 (0.62, 2.21)
P=0.62 P=0.63
Age at menarche (yrs)
    ≥14 27 (25.0) 83 (26.2) 1.00 11 (16.4) 49 (18.6) 1.00
    12 to 13 50 (46.3) 141 (44.5) 1.13 (0.63, 2.02) 32 (47.8) 146 (55.5) 0.84 (0.38, 1.83)
    <12 31 (28.7) 93 (29.3) 1.15 (0.61, 2.17) 24 (35.8) 68 (25.9) 1.41 (0.62, 3.22)
P-trend=0.68 P-trend=0.28
OC use (mos)
    0 44 (40.7) 123 (38.9) 1.00 28 (47.8) 91 (34.6) 1.00
    1 to 72 37 (34.3) 113 (35.8) 0.97 (0.56, 1.67) 24 (35.8) 94 (35.7) 0.83 (0.43, 1.63)
    >72 27 (25.0) 80 (25.3) 0.98 (0.54, 1.81) 15 (22.4) 78 (29.7) 0.68 (0.31, 1.48)
P-trend=0.62 P-trend=0.41
Postmenopausal MHT use
    No 33 (68.7) 121 (74.2) 1.00 16 (50.0) 72 (60.5) 1.00
    Yes 15 (31.3) 42 (25.8) 1.26 (0.58, 2.74) 16 (50.0) 47 (39.5) 2.06 (0.80, 5.30)
P=0.56 P=0.14
Current BMI (kg/m2), Premenopausal
    ≤25 13 (21.7) 30 (19.7) 1.00 16 (47.1) 71 (50.7) 1.00
    >25 to ≤30 14 (23.3) 48 (31.6) 0.46 (0.17, 1.23) 6 (17.6) 41 (29.3) 0.52 (0.17, 1.60)
    >30 33 (55.0) 74 (48.7) 0.64 (0.26, 1.57) 12 (35.3) 28 (20.0) 1.88 (0.64, 5.53)
P-trend=0.89 P-trend=0.68
Current BMI (kg/m2), Postmenopausal
    ≤25 12 (26.7) 23 (14.5) 1.00 12 (38.7) 42 (36.2) 1.00
    >25 to ≤30 16 (35.5) 43 (27.0) 0.62 (0.23, 1.69) 9 (29.0) 32 (27.6) 1.02 (0.33, 3.15)
    >30 17 (37.8) 93 (58.5) 0.33 (0.13, 0.86) 10 (32.3) 42 (36.2) 0.70 (0.23, 2.15)
P-trend=0.03 P-trend=0.53
Smoking
    No 72 (66.7) 193 (60.9) 1.00 36 (53.7) 137 (52.1) 1.00
    Current/Former 36 (33.3) 124 (39.1) 0.71 (0.41, 1.21) 31 (46.3) 126 (47.9) 0.95 (0.54, 1.70)
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AA EA
Pure IDC Mixed IDC/DCIS OR (95% CI)












    0 14 (12.3) 54 (15.5) 1.00 24 (35.8) 97 (32.1) 1.00
    1 22 (19.3) 85 (26.6) 0.78 (0.33, 1.84) 9 (13.4) 48 (15.9) 0.80 (0.30, 2.11)
    2 38 (33.3) 93 (26.7) 1.14 (0.52, 2.51) 22 (32.8) 97 (32.1) 1.06 (0.51, 2.21)
    ≥3 40 (35.1) 116 (33.3) 0.79 (0.35, 1.78) 12 (17.9) 60 (19.9) 0.65 (0.56, 1.65)
P-trend=0.79 P-trend=0.58
Age at first birth (yrs)
b
    ≤22 54 (58.7) 168 (62.9) 1.00 10 (23.8) 38 (21.4) 1.00
    >22 to ≤30 29 (31.5) 73 (27.3) 1.30 (0.72, 2.40) 20 (47.6) 83 (46.6) 0.81 (0.30, 2.16)
    >30 9 (9.78) 26 (9.7) 1.79 (0.72, 4.45) 12 (28.6) 57 (32.0) 0.76 (0.23, 2.49)
P-trend=0.67 P-trend=0.92
Age at last birth (yrs)
c
    ≤28 52 (56.5) 131 (49.1) 1.00 11 (26.2) 42 (23.6) 1.00
    >28 to ≤33 20 (21.7) 63 (23.6) 0.70 (0.36, 1.36) 15 (35.7) 66 (37.1) 0.82 (0.31, 2.16)




    None 52 (56.5) 132 (49.3) 1.00 23 (54.8) 61 (34.3) 1.00
    >0-12 25 (27.2) 78 (29.1) 0.69 (0.36, 1.33) 11 (26.2) 70 (39.3) 0.34 (0.14, 0.84)
    >12 15 (16.3) 58 (21.6) 0.47 (0.22, 1.04) 8 (19.0) 47 (26.4) 0.37 (0.14, 1.03)
P-trend=0.20 P-trend=0.25
Abbreviations: IDC, invasive ductal carcinoma; DCIS, ductal carcinoma in situ; ER, estrogen receptor; OR, Odds Ratio; CI, confidence interval; 
AA, African American; EA, European American; MHT, menstrual hormone therapy; BMI, body mass index
a
Unconditional logistic regression was used to estimate odds of having pure IDC versus mixed IDC/DCIS, with analyses adjusted for age, 
birthplace, family history, composite screening score, education, OC use, age at menarche, parity, menopausal status and ER status. Analysis of 
MHT use was not adjusted for menopausal status since only postmenopausal women were included in the analysis. Associations were adjusted for 
covariates listed above unless the covariate was the main exposure of interest or was used as a stratification variable.
b
Among 580 parous women only.
c
Among 580 women only, with an additional adjustment for age at first birth.
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Table 5
Associations between tumor characteristics and odds of pure IDC compared to mixed IDC/DCIS in the 
Women's Circle of Health Study (n=755)







    <45 52 (29.7) 164 (28.3) 1.00
    ≥45 123 (70.3) 416 (71.7) 1.17 (0.65, 2.11)
P=0.61
Tumor size (cm)
    <2 74 (49.7) 347 (63.7) 1.00
    2-<5 63 (42.3) 174 (31.9) 1.58 (1.07, 2.35)
    ≥5 12 (8.0) 24 (4.4) 2.16 (1.00, 4.67)
P-trend=0.008
Tumor grade
    1 22 (13.6) 91 (16.2) 1.00
    2 48 (29.6) 240 (42.7) 0.75 (0.43, 1.34)
    3 92 (56.8) 231(41.1) 1.49 (0.86, 2.57)
P-trend=0.01
TNM stage
    1 45 (38.8) 233 (49.8) 1.00
    2 58 (50.0) 169 (36.1) 1.63 (1.03, 2.57)
    3 13 (11.2) 66 (14.1) 0.87 (0.43, 1.75)
P-trend=0.63
Lymph nodes
    Negative 81 (68.1) 269 (58.2) 1.00
    Positive 38 (31.9) 193 (41.8) 0.55 (0.35, 0.87)
P=0.01
Lymphovascular invasion
    Negative 92 (73.6) 281 (64.3) 1.00
    Positive 33 (26.4) 156 (35.7) 0.58 (0.36, 0.92)
P=0.02
ER
    Positive 96 (54.9) 450 (77.6) 1.00
    Negative 79 (45.1) 130 (22.4) 2.79 (1.93, 4.05)
P<0.0001
PR
    Positive 88 (50.9) 370 (66.3) 1.00
    Negative 85 (49.1) 188 (33.7) 1.87 (1.30, 2.68)
P=0.0008
HER2
    Negative 136 (84.0) 415 (77.9) 1.00
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    Positive 26 (16.0) 118 (22.1) 0.65 (0.41, 1.05)
P=0.08
Breast cancer subtypes
    Luminal A 79 (49.1) 341 (64.2) 1.00
    Luminal B 14 (8.70) 78 (14.7) 0.78 (0.41, 1.46)
    Nonluminal 12 (7.45) 40 (7.53) 1.30 (0.64, 2.63)
    Triple negative 56 (34.8) 72 (13.6) 3.26 (2.08, 5.12)
P<0.0001
Method of tumor discovery
    Mammogram 53 (32.5) 231 (43.7) 1.00
    Palpation 110 (67.5) 298 (56.3) 1.54 (1.02, 2.32)
P=0.04
Abbreviations: IDC, invasive ductal carcinoma; DCIS, ductal carcinoma in situ; OR, Odds Ratio; CI, confidence interval; ER, estrogen receptor; 
PR, progesterone receptor; HER2, human epidermal growth factor 2, OC, oral contraceptive
a
Unconditional logistic regression models were used to estimate ORs and 95% CIs. All models were adjusted for age, race, birthplace, family 
history, composite screening score, education, OC use, age at menarche, parity and menopausal status. Associations were adjusted for covariates 
listed above unless the covariate was the main exposure of interest.
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